Targeting MAGI2‐AS3‐modulated Akt‐dependent ATP‐binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide‐resistant glioblastoma cells
Drug Development Research · 2023
DOI: 10.1002/ddr.22101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2023. Verfasst von Zhongjun Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Affiliated Huai'an Hospital of Xuzhou Medical University, The Second People's Hospital of Huai'an, Huai'an, Jiangsu, …. Hauptthemen laut MEDLINE: Glioblastoma, Glioma, MicroRNAs, RNA, Long Noncoding. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Abstract (Originalsprache)
Drug resistance is a major impediment to the successful treatment of glioma. This study aimed to elucidate the effects and mechanisms of the long noncoding RNA membrane‐associated guanylate kinase inverted‐2 antisense RNA 3 (MAGI2‐AS3) on temozolomide (TMZ) resistance in glioma cells. MAGI2‐AS3 expression in TMZ‐resistant glioblastoma (GBM) cells was analyzed using the Gene Expression Omnibus data set GSE113510 and quantitative real‐time PCR (qRT‐PCR). Cell viability and TMZ half‐maximal inhibitory concentration values were determined using the MTT assay. Apoptosis and cell cycle distribution were evaluated using flow cytometry. The expression of multidrug resistance 1 (MDR1), ATP‐binding cassette superfamily G member 2 (ABCG2), protein kinase B (Akt), and phosphorylated Akt was detected using qRT‐PCR and/or western blot analysis. MAGI2‐AS3 was expressed at low levels in TMZ‐resistant GBM cells relative to that in their parental cells. MAGI2‐AS3 re‐expression alleviated TMZ resistance in TMZ‐resistant GBM cells. MAGI2‐AS3 overexpression also accelerated TMZ‐induced apoptosis and G2/M phase arrest. Mechanistically, MAGI2‐AS3 overexpression reduced MDR1 and ABCG2 expression and inhibited the Akt pathway, whereas Akt overexpression abrogated the reduction in MDR1 and ABCG2 expression induced by MAGI2‐AS3. Moreover, activation of the Akt pathway inhibited the effects of MAGI2‐AS3 on TMZ resistance. MAGI2‐AS3 inhibited tumor growth and enhanced the suppressive effect of TMZ on glioma tumorigenesis in vivo. In conclusion, MAGI2‐AS3 reverses TMZ resistance in glioma cells by inactivating the Akt pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The Affiliated Huai'an Hospital of Xuzhou Medical University, The Second People's Hospital of Huai'an, Huai'an, Jiangsu, China.
- Emergency Department, The Fifth People's Hospital of Huai'an, Huai'an, Jiangsu, China.
- Department of Neurosurgery, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
ORCID-Profile: Hongzao Ni, Botao Zhou
Zitieren
APA
Chen, Z., Zhou, J., Liu, Y., Ni, H., & Zhou, B. (2023). Targeting MAGI2‐AS3‐modulated Akt‐dependent ATP‐binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide‐resistant glioblastoma cells. Drug Development Research. https://doi.org/10.1002/ddr.22101
Vancouver
Chen Z, Zhou J, Liu Y, Ni H, Zhou B. Targeting MAGI2‐AS3‐modulated Akt‐dependent ATP‐binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide‐resistant glioblastoma cells. Drug Development Research. 2023. doi:10.1002/ddr.22101
BibTeX
@article{Chen2023,
author = {Chen, Zhongjun and Zhou, Jingmin and Liu, Yu and Ni, Hongzao and Zhou, Botao},
title = {Targeting MAGI2‐AS3‐modulated Akt‐dependent ATP‐binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide‐resistant glioblastoma cells},
journal = {Drug Development Research},
year = {2023},
doi = {10.1002/ddr.22101}
}
EUVIMED